A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
about
Taxane-containing regimens for metastatic breast cancerSystematic review of ixabepilone for treating metastatic breast cancer.Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC.The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
P2860
Q24187214-A1589253-BF9E-4196-9D41-D87A42841424Q30248627-618D0657-52BE-49C0-B495-2C52BBC172F9Q35047223-DA37A473-BE1C-4A10-BCFA-8B86E332E376Q35847455-89C65D1A-1368-4022-86B5-3851EBF4D69BQ36372761-9DE19B4F-C1BB-486E-B418-DAC79B1BBA11Q37148642-D0DD5E33-D4AD-4A66-900B-46075E97E237Q37722656-0C3A7D6B-4A11-4D00-9847-F21D29EBC49AQ38527538-835E9351-4163-4A08-83AE-6BABE694FE03Q39089103-1B852376-C687-4A1E-A163-7A9D0FC9C333Q50221869-488E3395-11C0-495A-869C-589F204585AAQ50908788-DAA8EB31-D187-478B-B225-E28B87751A9FQ53384579-89F4273D-5B3E-4B47-9FD5-43B5F5C850A7Q54374887-721D226C-6478-4BB5-88E4-A9E1BAE18732
P2860
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A randomized, phase II, three- ...... for metastatic breast cancer.
@en
type
label
A randomized, phase II, three- ...... for metastatic breast cancer.
@en
prefLabel
A randomized, phase II, three- ...... for metastatic breast cancer.
@en
P2093
P2860
P50
P1476
A randomized, phase II, three- ...... y for metastatic breast cancer
@en
P2093
Cristian Villanueva
Daniela Aldrighetti
Dino Amadori
Francis Lee
Hope S Rugo
M Brent McHenry
Mario Campone
Michelle Melisko
P2860
P2888
P304
P356
10.1007/S10549-013-2552-8
P407
P577
2013-05-07T00:00:00Z